Acetylcholine mediates a variety of responses in the central nervous system and throughout the body via muscarinic receptors. Five subtypes of muscarinic receptors, belonging to the family of G-protein-coupled receptors, have been identified through molecular biological studies. Although much is known about the biochemical and physiological responses elicited or prevented by muscarinic receptor ligands, comparatively little is known regarding the interaction of agonists and antagonists with muscarinic receptor subtypes at the molecular level. Such information is vital for efforts to develop selective ligands for the treatment of neurological disorders such as Alzheimer's disease. The present proposal focuses on understanding the interaction of ligands with muscarinic receptor subtypes at the molecular level. Molecular modeling and computational chemical approaches will be used to develop models of muscarinic receptor subtypes for use in docking studies. Biochemical studies will examine the binding affinities and agonist activities of ligands at muscarinic receptor subtypes expressed in cell lines. Molecular biological approaches will be used to generate receptors with point mutations to examine further the interaction of ligands with key amino acid residues on muscarinic receptor subtypes. Chemical synthesis will focus on a few key compounds with the aim of exploring the molecular features important for ligand binding and activity. Quantitative structure activity studies will help identify the molecular features which contribute to ligand activity and provide a basis for the rational design and synthesis of new ligands. The overall goal of the proposed studies is to identify molecular features important for ligand affinity and agonist activity at muscarinic receptor subtypes. These studies will be helpful in generating new compounds with improved selectivity for muscarinic receptor subtypes, and aid in the development of novel ligands for the treatment of Alzheimer's disease and other neurological disorders.

National Institute of Health (NIH)
National Institute of Neurological Disorders and Stroke (NINDS)
Research Project (R01)
Project #
Application #
Study Section
Neurological Sciences Subcommittee 1 (NLS)
Program Officer
Oliver, Eugene J
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of Toledo
Schools of Pharmacy
United States
Zip Code
Nagy, Peter I; Messer, William S (2011) Theoretical studies of the in-solution isomeric protonation of non-aromatic six-member rings with two nitrogens. J Phys Chem B 115:4758-67
Tejada, Frederick R; Nagy, Peter I; Xu, Min et al. (2006) Design and synthesis of novel derivatives of the muscarinic agonist tetra(ethylene glycol)(3-methoxy-1,2,5-thiadiazol-4-yl) [3-(1-methyl-1,2,5,6-tetrahydropyrid-3-yl)-1,2,5-thiadiazol-4-yl] ether (CDD-0304): effects of structural modifications on the bind J Med Chem 49:7518-31
Cao, Yang; Zhang, Minjia; Wu, Cindy et al. (2003) Synthesis and biological characterization of 1-methyl-1,2,5,6-tetrahydropyridyl-1,2,5-thiadiazole derivatives as muscarinic agonists for the treatment of neurological disorders. J Med Chem 46:4273-86
Rajeswaran, W G; Cao, Y; Huang, X P et al. (2001) Design, synthesis, and biological characterization of bivalent 1-methyl-1,2,5,6-tetrahydropyridyl-1,2,5-thiadiazole derivatives as selective muscarinic agonists. J Med Chem 44:4563-76
Messer Jr, W S; Rajeswaran, W G; Cao, Y et al. (2000) Design and development of selective muscarinic agonists for the treatment of Alzheimer's disease: characterization of tetrahydropyrimidine derivatives and development of new approaches for improved affinity and selectivity for M1 receptors. Pharm Acta Helv 74:135-40
Huang, X P; Williams, F E; Peseckis, S M et al. (1999) Differential modulation of agonist potency and receptor coupling by mutations of Ser388Tyr and Thr389Pro at the junction of transmembrane domain VI and the third extracellular loop of human M(1) muscarinic acetylcholine receptors. Mol Pharmacol 56:775-83